<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Nizatidine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00585</strong>&#160; (APRD00706)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00585/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00585/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00585.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00585.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00585.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00585.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00585.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00585">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Nizatidina</td><td>Spanish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nizatidine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN, JAN</td></tr><tr><td>Nizatidinum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Acinon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Axid</td><td>Eli Lilly</td></tr><tr><td>Tazac</td><td>Eli Lilly</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-ulcer-agents">Anti-Ulcer Agents</a></li>
<li><a href="/mesh/histamine-h2-antagonists">Histamine H2 Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>76963-41-2</td></tr><tr><th>Weight</th><td>Average: 331.457<br>Monoisotopic: 331.113666321</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>SGXXNSQHWDMGGP-IZZDOVSWSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">dimethyl[(4-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C/[N+]([O-])=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Thiazoles</td></tr><tr><th>Direct parent</th><td>2,4-disubstituted Thiazoles</td></tr><tr><th>Alternative parents</th><td>Nitro Compounds; Tertiary Amines; Nitronic Acids; Polyamines; Organic Oxoazanium Compounds; Thioethers</td></tr><tr><th>Substituents</th><td>nitronic acid; nitro compound; tertiary amine; organic oxoazanium; polyamine; thioether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at positions 2 and 4 only.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.</td></tr><tr><th>Pharmacodynamics</th><td>Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.</td></tr><tr><th>Mechanism of action</th><td>Nizatidine competes with histamine for binding at the H<sub>2</sub>-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.</td></tr><tr><th>Absorption</th><td>Rapid (bioavailability of nizatidine exceeds 70%)</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.8 to 1.5 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>35%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Nizatidine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00959">N2-monodes-methylnizatidine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/980">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>1-2 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>40-60 L/h</li>
	<li>7 &#8211; 14 L/h [functionally anephric patients]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Oral, rat LD<sub>50</sub>: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Nizatidine Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9572</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.589</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8357</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8947</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8861</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7832</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8108</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6721</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5916</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9072</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8508</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7826</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6129
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9182
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9295
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4350 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.6244
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8734
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Smithkline beecham corp dba glaxosmithkline</li>
<li>Apotex inc</li>
<li>Dr reddys laboratories ltd</li>
<li>Genpharm inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Braintree laboratories inc</li>
<li>Amneal pharmaceuticals</li>
<li>Wyeth consumer healthcare</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.affordablepharm.com">Affordable Pharmaceuticals LLC</a></li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.braintreelabs.com">Braintree Laboratories Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li>Eon Labs</li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.lyne.com">Lyne Laboratories Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li>Promex Medical Inc.</li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Reliant Pharmaceuticals</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.wyeth.com">Wyeth Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB01066">Cefditoren</a></td><td>H2-Antagonists such as nizatidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.</td></tr><tr><td><a href="/drugs/DB00467">Enoxacin</a></td><td>Nizatidine may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>The H2-receptor antagonist, nizatidine, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>The H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid excessive quantities of coffee or tea (Caffeine).</li>
<li>Do not take Aluminum or magnesium antacids or supplements while on this medication.</li>
<li>May take Vitamin D.</li>
<li>No iron, zinc or fluoride within 2 hours of taking this medication.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>